Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects
Status:
Completed
Trial end date:
2009-10-09
Target enrollment:
Participant gender:
Summary
GSK1144814 is a potent, insurmountable antagonist at human neurokinin-1 (NK1) and
neurokinin-3 (NK3) receptors with the potential to treat multiple symptom domains of
schizophrenia and be an efficacious antidepressant.
This study will be an open label, randomised, three-way cross-over study to evaluate the
safety, tolerability and pharmacokinetics of a new tablet formulation of GSK1144814 and to
evaluate the effect of food on single oral doses of GSK1144814 in healthy male and female
subjects.